Discover 870 paid clinical trials in Tuscaloosa, Alabama. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 870
Active & Responsive
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
for
Metastatic Hepatocellular Carcinoma,
Location: Birmingham AL, Nashville TN, Houston TX, Zion IL,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06427941
Phase 1, Phase 2, Recruiting
Active & Responsive
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
for
Non-small Cell Lung Cancer
Location: Birmingham AL, Elizabethtown KY, Tampa FL, New York NY
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT06841055
Phase 2, Recruiting
Active & Responsive
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
for
Alzheimer Disease
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham
Sex: All
Age: 50+
Code: NCT03503331
Phase 2, Recruiting
Active & Responsive
Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch Syndrome
for
Cascade Testing, Lynch Syndrome, Decision Making,
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham
Sex: All
Age: 18+
Code: NCT07106359
Recruiting
Active & Responsive
The Effect of a Daily Magnesium and Melatonin Supplement on Sleep Quality in People With Nighttime Leg Cramps
for
Poor Sleep Quality, Leg Cramps, Nocturnal
Location: Birmingham AL, Atlanta GA, Nashville TN, Little Rock AR,
Sponsor: StudySetGo
Sex: All
Age: 40 - 70+
Code: NCT07651514
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer